Squamous NSCLC
Scottish Cancer Network: Clinical Management Pathways
Throughout the patient pathway, consideration should be given to patient preference, performance status and other relevant patient factors.
Patient eligibility and suitability for available clinical trials should be considered and discussed with individual patients as appropriate.
| Date of creation | 20/09/2023 | Version number | 1.0 |
| Author | Nicola Steele (on behalf of SACT subgroup) | Reviewer | John Maclay |
|
Updated |
28/05/2024 |
Version number | 1.2 |
| Author | Nicola Steele (on behalf of SACT subgroup) | Approval | Editorial Group |
| Description of last update | Section: PDL1>=50% NSCLC Stage III/IV squamous Correction of previous omission of paclitaxel as 2nd line option for Stage IV- no Prior SACT. |
||
| Review Date | 20/09/2026 | Contact | nss.scottishcancernetwork@nhs.scot |